Enterra Medical

Enterra Medical is a private medical device company commercializing the Enterra Therapy System, a humanitarian use device (HUD) for treating chronic, medication-resistant nausea and vomiting due to gastroparesis. The company originated from Medtronic's technology, which received FDA approval in 2000, and was established as an independent entity to drive innovation and support for this underserved patient population. With over 15,000 devices implanted, Enterra operates in a niche but significant market with limited direct device competition, though it faces challenges related to the device's humanitarian designation, which means effectiveness is not proven. Its strategy revolves around patient and physician education, provider network development, and leveraging real-world evidence to support therapy adoption.

Implantable Gastric Electrical Stimulation (GES) system delivering high-frequency, low-energy pulses to stomach muscles to reduce chronic nausea and vomiting associated with gastroparesis.

Direct competition for an implantable GES device is limited. However, the therapy competes with pharmacological management (prokinetic/anti-emetic drugs), dietary interventions, and alternative surgical procedures like gastric bypass or G-POEM. New drug developments or endoscopic techniques represent the most likely competitive threats.